US-based biopharmaceutical company Pfizer has filed a registration statement with the US Securities and Exchange Commission (SEC) for a public offering of securities.

Pfizer will offer debt securities, common stock, preferred stock, warrants, depositary shares, purchase contracts, purchase units or guarantees from time to time.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company plans to use the proceeds for general corporate purposes, including working capital, debt repayment, dividend payment and acquisitions.

UK-based pharmaceutical company N4 Pharma has issued 716,000 shares priced at £0.085 ($0.12) a share in a private placement to raise £0.06m ($0.08m).

Tesaro has signed a clinical collaboration agreement with Roche’s subsidiary Genentech to evaluate the combination of the PD-L1 antibody atezolizumab (TECENTRIQ) and PARP-inhibitor ZEJULA (niraparib) in patients with metastatic bladder cancer.

The collaboration also includes testing Roche’s cancer immunotherapy MORPHEUS, which is currently under phase Ib/II development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The company plans to use the proceeds for general corporate purposes, including working capital, debt repayment, dividend payment and acquisitions.”

Both companies involved in the transaction are biotechnology companies based in the US.

US-based biopharmaceutical company CASI Pharmaceuticals has issued shares of its common stock in a public offering to raise $25m.

The company plans to use the proceeds for general corporate purposes, including research and development, commercialisation, business development and acquisitions.

CASI has appointed H.C. Wainwright & Co. as underwriter, and Arnold & Porter Kaye Scholer as legal advisor for the transaction.

Taiwanese pharmaceutical company Gongwin Biopharm Holdings has issued 4.95 million shares priced at TW$54 ($1.85) a share in a rights offering to raise TW$267.3m ($9.13m).

The company will issue 5.5 million shares to its employees and 4.95 million shares to shareholders.

Gongwin Biopharm plans to use the proceeds for working capital and to fund various research and development (R&D) projects.